Testosterone is the most oversold and most misunderstood hormone in midlife women's health. It is marketed as a fix for fatigue, mood, muscle, and motivation — but the evidence supports it for exactly one thing, and there is still no FDA-approved testosterone product for women in the United States. Here is the honest picture, so you can have a realistic conversation rather than a sales one.
Where we stand: Menova is an independent publication. We sell no hormones, we are not your doctor, and this is general education, not medical advice. We have no financial interest in whether you take testosterone.
Do women need testosterone?
Yes — women produce testosterone throughout life, from the ovaries and adrenal glands, and levels decline gradually with age. That decline starts well before menopause and is not a sudden cliff at your final period, which is why "menopause caused my low testosterone" is a simplification.
The important distinction: having a lower level than you did at 25 is normal aging, not automatically a deficiency requiring treatment. There is no established blood level that defines "low testosterone" in women, and no threshold at which treatment is indicated. This is genuinely different from the situation in men, which we cover separately in low testosterone symptoms in men.
What testosterone is actually supported for
International consensus among menopause and endocrine societies is narrow and clear: the only evidence-based indication for testosterone in women is hypoactive sexual desire disorder (HSDD) in postmenopausal women — distressing low sexual desire that is not explained by relationship issues, medication, mood, or other causes.
For that indication, trials show a modest but real improvement in desire, arousal, and satisfying sexual events. Modest is the honest word: it is a meaningful difference for some women, not a transformation for most.
Two conditions usually apply before it is considered. First, other causes are addressed — including vaginal dryness and pain, which are extremely common, treatable, and frequently the real reason desire dropped. Our articles on low libido and vaginal dryness and genitourinary syndrome of menopause cover this, and it is worth ruling out before adding a hormone. Second, systemic estrogen therapy is often optimized first.
What testosterone is not supported for
This is where marketing outruns evidence. Current guidance from menopause societies states there is insufficient evidence to recommend testosterone in women for:
- Fatigue or low energy
- Mood, depression, or wellbeing
- Cognitive function or brain fog
- Bone density
- Muscle mass, body composition, or athletic performance
- Cardiovascular or metabolic health
That does not mean it definitely does nothing for these. It means the studies needed to say so do not exist, and any clinic presenting testosterone as a proven treatment for fatigue or brain fog is going beyond what is known. If those are your main symptoms, the higher-yield path is working through the common causes — our pieces on why brain fog happens and when menopause might not be the answer cover thyroid, iron, sleep, and mood, all of which are more likely and more treatable.
How it is prescribed when there is no approved product
In the US, no testosterone formulation is FDA-approved for women. In practice, clinicians who prescribe it use a small fraction of an approved male product — typically a transdermal gel dosed at roughly a tenth of the male dose — or a compounded preparation. Both are off-label.
Two practical points from this:
- Delivery matters. Transdermal dosing is generally preferred. Oral testosterone is not recommended because of effects on liver and lipids.
- Pellets and high-dose compounding are a common source of harm. Implanted pellets deliver doses that cannot be adjusted or removed if levels run high, and supraphysiologic levels are where side effects concentrate. Our article on compounded versus FDA-approved hormone therapy explains the wider issue.
Side effects and monitoring
At physiologic doses — meaning doses that return you to a normal premenopausal range, not above it — testosterone is generally well tolerated. Side effects are dose-dependent and cluster at higher levels: acne, oily skin, unwanted hair growth at the application site or on the face, and, with sustained excess, voice deepening and clitoral enlargement, which may not fully reverse.
Reasonable monitoring looks like a baseline level, a repeat level after starting to confirm you are not above the female physiologic range, and periodic checks thereafter. A clinician who prescribes without measuring, or who aims for levels "in the male range" or "optimal" ranges of their own invention, is not following the evidence.
Long-term safety data — particularly on breast and cardiovascular outcomes — is limited, because the trials are short. That uncertainty is a reason for honest conversation, not panic, and it belongs in your decision.
How to have the conversation
If low desire is genuinely distressing you and you have addressed pain, dryness, sleep, relationship factors, and medications that lower libido (SSRIs are a frequent culprit), testosterone is a legitimate thing to raise with a menopause-trained clinician. Ask three questions: what will we treat, how will we measure it, and when do we stop if it does not help.
Finding someone who will engage with that instead of reflexively dismissing you — or reflexively selling you pellets — is the real difficulty. Our guide to finding a clinician who actually knows menopause covers how, and our independent comparison of menopause telehealth services shows which ones employ clinicians with menopause credentials. The free 2-minute self-check helps you arrive with your symptom picture organized.
This article is general education, not medical advice, and not a recommendation that you take or avoid testosterone. Off-label prescribing decisions, dosing, and monitoring belong with a licensed clinician who knows your full history.
Sources: The Menopause Society, Global Consensus Position Statement on the Use of Testosterone Therapy for Women, ACOG, and NHS.